Trial Profile

Phase III Randomized Trial of Maintenance Pegylated Liposomal Doxorubicin (PLD) / Carboplatin versus without in Patients with Advanced Ovarian Cancer.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin liposomal (Primary) ; Carboplatin
Indications Ovarian cancer
Focus Therapeutic Use
Sponsors TTY Biopharm

Most Recent Events

05 Jun 2018 Primary endpoint (Progression-free survival) has been met, according to the results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
20 Mar 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com